Alternative to Impavido in Malaysia
The best equivalent of Impavido in Malaysia called Alimta. Analogue has exactly the same pharmacological group
You can buy Alimta (alternative to Impavido) in pharmacies of Malaysia.
Attention! Always consult to a doctor or pharmacist before using pills or medicines.
Where to buyMedically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2020.01.09

Ecuador
Ingredients
Miltefosine
Treatment option
Pharmacological group
partial
equal

Malaysia
Ingredients
Pemetrexed
Treatment option partial
Pharmacological group equal
Where to buy Impavido or alternative in Malaysia
To buy Impavido or its alternatives in Malaysia, we recommend to contact your nearest pharmacy. Call the pharmacy using the number on the map, to find out if Impavido is in stock. Remember to ask the pharmacist about the price of the medicine and the requirement to provide a prescription, many medicines in Malaysia are sold strictly according to the doctor's prescription. Show pharmacy near me.
Show pharmacy near me
Pillintrip.com is not a pharmacy!
Advertisements
Advertisements
Other analogues
| Name | Ingredients | Treatment option | Pharmacological group | ||
| Alimta | 50% | ||||
| Arimidex | 50% | ||||
| Aromasin | 50% | ||||
| Caelyx (ANTINEOPLASTIC) | 50% | ||||
| Campto | 50% | ||||
| Casodex | 50% | ||||
| Certican | 50% | ||||
| Eligard | 50% | ||||
| Eloxatin | 50% | ||||
| Eposin | 50% | ||||
| Erbitux | 50% | ||||
| Faslodex | 50% | ||||
| Firmagon | 50% | ||||
| Fluracedyl | 50% | ||||
| Halaven | 50% | ||||
| Hycamtin | 50% | ||||
| Inlyta | 50% | ||||
| Iressa | 50% | ||||
| Jevtana | 50% | ||||
| Lastet | 50% | ||||
| Mitomycin-C Kyowa | 50% | ||||
| Nexavar | 50% | ||||
| Nolvadex D | 50% | ||||
| Nolvadex-D | 50% | ||||
| Suprefact | 50% | ||||
| Sutent | 50% | ||||
| Taxotere | 50% | ||||
| Tekamen | 50% | ||||
| Tykerb | 50% | ||||
| Vectibix | 50% | ||||
| Votrient | 50% | ||||
| Yondelis | 50% | ||||
| Zoladex | 50% | ||||
| Zoladex LA | 50% | ||||
| Caelyx | 50% |
Advertisements
Advertisements
Advertisements
Advertisements

